Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2141-2150 Newer>

The Motley Fool June 29, 2005 Stephen D. Simpson	CardioDynamics Needs Growth, Stat! CardioDynamics no longer deserves the benefit of the doubt until it produces some growth. Long-suffering investors shouldn't expect the cavalry to be arriving anytime soon.
The Motley Fool June 28, 2005 Stephen D. Simpson	A Boost for Wyeth Wyeth raises full-year expectations for the second time. Perhaps this is a peek at what's to come for investors in other pharmaceuticals, too.
The Motley Fool June 28, 2005 Charly Travers	Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note.
The Motley Fool June 28, 2005 Lawrence Meyers	It's All Positive for PPDI Pharmaceutical Product Development continues to pump out the cash flow and rake in business. Investors, take note.
The Motley Fool June 28, 2005 Brian Gorman	Cardinal Changes Course The health care company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
Pharmaceutical Executive June 1, 2005 Doretta Gasorek	Who Sees the Halo? Insiders say pharma ethics reputations shine. Consumers don't see the glow.
Pharmaceutical Executive June 1, 2005 Sibyl Shalo	Chief of Staph Nabi, a small pharmaceutical company, has found a way to make money by making vaccines. Nabi now aims to become the first company to market a vaccine to attack the deadly staph bacterium.
Pharmaceutical Executive June 1, 2005 Ian Wilcox	Raising Renaissance Managers The leaders of pharma lack vision because of the industry's practice of promoting specialists to top positions. Talent management strategies can reverse this trend and lead to greater success.
Pharmaceutical Executive June 1, 2005	Thought Leader: Molecular Stewardship You often hear about executives that follow their mentors from one company to another. But Paul Duffy, a 31-year veteran of Sandoz--and then Novartis-- followed a molecule to his new post as executive vice president of Alamo Pharmaceuticals.
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay	Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole.
<Older 2141-2150 Newer> Return to current articles.